Theriva Biologics, Inc. (TOVX)

NYSEAMERICAN: TOVX · Real-Time Price · USD

0.2350

+0.0048 (2.09%)

Aug 21, 2026, 4:00 PM EDT - Market closed

Theriva Biologics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-11.62	-23.74	-25.65	-18.35	-19.69	-14.27
Depreciation & Amortization	0.1	0.11	0.14	0.14	0.09	0.09
Loss (Gain) From Sale of Assets	0	0	-	-	-	-
Asset Writedown & Restructuring Costs	-	-	6.92	-	-	-
Stock-Based Compensation	0.65	0.65	0.67	0.55	0.48	0.42
Other Operating Activities	0.03	9.37	0.26	-3.64	0.85	0.17
Change in Accounts Payable	0.36	0.07	0.12	-0.16	-0.39	-0.36
Change in Other Net Operating Assets	-2.27	-3.13	0.6	2.47	-0.42	1.07
Operating Cash Flow	-12.74	-16.67	-16.94	-19	-19.08	-12.89
Operating Cash Flow Growth	-	-	-	-	-	-

Investing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Capital Expenditures	-0.02	-0.04	-0	-0.2	-0.12	-0.01
Cash Acquisitions	-	-	-	-	-3.86	-
Investing Cash Flow	-0.02	-0.04	-0	-0.2	-4.4	-0.01

Financing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Long-Term Debt Issued	-	1.51	-	-	-	-
Long-Term Debt Repaid	-	-0.07	-0.07	-0.08	-1.38	-
Net Debt Issued (Repaid)	-0.01	1.44	-0.07	-0.08	-1.38	-
Issuance of Common Stock	13.08	17.47	5.56	2.22	-	74
Repurchase of Common Stock	-	-	-	-	-0.29	-
Other Financing Activities	-0.9	-0.71	-	-1.52	-3	-
Financing Cash Flow	12.16	18.19	5.5	0.63	-1.93	74

Net Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Foreign Exchange Rate Adjustments	-0.18	-0.09	-0.13	-0.03	-0.03	-
Net Cash Flow	-0.79	1.4	-11.57	-18.61	-25.44	61.1

Free Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-12.76	-16.7	-16.94	-19.2	-19.2	-12.9
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Per Share	-0.41	-1.38	-12.56	-29.80	-31.31	-26.47
Levered Free Cash Flow	-6.69	-5.98	-10.55	-14.41	-10.42	-7.51
Unlevered Free Cash Flow	-6.69	-5.98	-10.55	-14.41	-10.42	-7.51

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Change in Working Capital	-1.91	-3.06	0.73	2.31	-0.81	0.71

SEC Filings: 10-K · 10-Q